For patients  /  Stroke
Stroke condition hub

Stroke clinical trials, explained for patients.

How trials work, what's new in stroke research this year, and where to find recovery and support resources along the way. Built in partnership with The Stroke Foundation.

Free, private, no obligation at any step.

The basics

Types of stroke clinical trials

Stroke trials test different things. Most fall into one of three groups, and each asks something different of the people who take part.

Observational studies

Researchers follow people over time without changing their treatment, using check-ups, brain scans, blood tests, or questionnaires. Examples include tracking how speech or movement recovers in the year after a stroke, or studying which health factors predict a second stroke.

Medication trials

Test new drugs, or new uses for existing ones, against standard care or a placebo. Examples include blood thinners to prevent a second stroke, clot-busting drugs given during emergency treatment, and drugs designed to protect brain cells in the first hours after a stroke.

Lifestyle & rehabilitation trials

Test therapy, exercise, and everyday activities that support recovery. Examples include new physical, occupational or speech therapy programs, walking or strength-training plans, and video games, apps or virtual reality used to practise arm movement, balance or memory at home.

Trials are specific to your type of stroke

Ischemic stroke A blood clot blocks an artery and cuts off blood flow to part of the brain. It makes up over 80% of all strokes. Trials often test faster ways to remove or dissolve clots, and medications that stop new clots from forming.
Hemorrhagic stroke An artery in the brain bursts or leaks, and the blood puts pressure on nearby brain cells. High blood pressure is a major risk factor. Research often looks at stopping the bleeding early and keeping blood pressure under control.
Transient ischemic attack (TIA or mini-stroke) Blood flow to the brain is blocked for only a few minutes, and the symptoms pass, but a TIA is a warning sign of a future stroke. Trials often focus on preventing a full stroke through medication or lifestyle changes.

Not sure which type you had? Your neurologist or stroke care team can confirm your diagnosis and help you see which trials apply to you.

Reasons for hope

What's new in stroke research this year

Four developments from 2026 worth knowing about, spanning prevention, emergency treatment, and recovery, in plain language:

Phase 3 · OCEANIC-STROKE trial Ischemic stroke · prevention

Asundexian

Published in NEJM, April 2026

A new type of blood thinner (a Factor XIa inhibitor) lowered the risk of a second ischemic stroke by 26% without increasing major bleeding, in a trial of more than 12,300 stroke survivors run largely out of Canada's Population Health Research Institute. Not yet approved.

Read the research summary →
CHOICE2 trial Ischemic stroke · emergency treatment

Clot-busting medication after clot removal

Better odds of excellent recovery at 90 days

Giving the clot-busting drug alteplase directly into the brain artery after a successful thrombectomy increased the number of patients who made an excellent recovery at 90 days.

Read the research summary →
BCI-REHAB trial Rehabilitation

At-home brain-computer interface therapy

Recovery is still possible years after a stroke

Survivors an average of five years past their stroke used a non-invasive brain-signal headset for arm therapy at home. After 12 weeks, 55.5% reached a meaningful improvement in arm function compared with 9.6% on a standard home exercise program.

Read the research summary →
Phase 3 · LAIS trial Ischemic stroke · acute treatment

Loberamisal

Preliminary results from a trial of 998 adults in China

A drug designed to protect brain cells, started within 48 hours of an ischemic stroke, led to excellent recovery at 90 days in about 69% of patients versus 56% on placebo.

Read the research summary →
The basics

How stroke clinical trials work

Clinical trials move through phases, and each one tests something different before a treatment can reach patients broadly:

Phase 1 Roughly 20–100 people

A small group — often including healthy volunteers alongside stroke survivors — tests safety, tolerability, and dosing. It's the first time the treatment is given to people.

Phase 2 100–300 people

Tests whether the treatment actually works, while continuing to monitor safety and side effects.

Phase 3 300 to several thousand

A large, diverse group confirms effectiveness, often comparing the new treatment to standard care or placebo. Usually the step required before regulatory approval.

Phase 4 After approval

The treatment is monitored in real-world use for long-term safety and rare side effects.

In every phase, three things stay constant: an informed consent process (a full explanation of purpose, risks, and benefits before you agree to participate), regular monitoring visits, and your right to withdraw at any time.
Decoding the fine print

What eligibility criteria mean

Every trial lists two kinds of rules. Here's how to read them:

Inclusion criteria

What most trials look for
  • A confirmed stroke diagnosis and type (ischemic, hemorrhagic, or TIA)
  • Independent living before your stroke
  • A specific deficit, such as arm weakness, aphasia, or difficulty walking
  • Specific prior treatments

Exclusion criteria

What might rule you out of a specific trial
  • Certain other health conditions
  • Certain current medications, such as some blood thinners
  • Pregnancy
  • Lab values or brain scan findings outside a safe range
Worth repeating: these rules exist to protect participant safety and to keep the study's results reliable. They are not a judgment on you, and not qualifying for one trial doesn't mean you won't qualify for another.
You're not doing this alone

Trusted stroke resources

Support for the whole journey: learning, funding, and community, from our partner The Stroke Foundation and others.

Learn about stroke

From The Stroke Foundation and Heart & Stroke

Financial & disability support

Programs that can ease the cost of care

Community & emotional support

For survivors, caregivers, and families

Not sure where to start? Talk to someone.

March of Dimes Canada's After Stroke Warmline can answer questions and point you toward the right resources or support groups.

CANADA After Stroke Warmline 1-888-540-6666
Before your first call

Tips for getting started

  • Found something on MyTrials that looks right? Your next step is your neurologist or stroke care team. Print or share the trial details and ask: "Is this worth exploring for me?" Doctors take patient-initiated trial questions seriously, and yours knows your history.
  • Contact the trial team with your information ready: your current medications, recent scans or lab results, and a brief history of your stroke and treatments you've tried. That's the first thing every coordinator asks for.
  • Use the tools below before your first call. The prep sheet, checklist, and consent guide were built for exactly this moment. Good trial teams expect these questions.

The 9-question checklist

The questions to ask any trial team before joining, with space to write their answers.

Download

Appointment prep sheet

One page to organize your medications, history, and questions before a screening visit.

Download

Consent form review sheet

A guided worksheet for reading a consent document at home before signing anything.

Download
The research updates and resources on this page are for information only and are not medical advice. Always talk to a neurologist or stroke care team before enrolling in any trial.

See which stroke trials fit your situation

Answer a few questions about your stroke, your treatments, and where you live. We'll show you what's recruiting, in plain language.

Free for patients. Private. No obligation at any step.